Literature DB >> 1311588

Reduced topoisomerase II and elevated alpha class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C.

P R Hoban1, C N Robson, S M Davies, A G Hall, A R Cattan, I D Hickson, A L Harris.   

Abstract

We have isolated a multidrug-resistant derivative of Chinese hamster ovary CHO-K1 cells by exposure to progressively increasing concentrations of Adriamycin. This cell line, designated CHO-Adrr, was 27-fold more resistant than the parental line to Adriamycin and showed similar degrees of cross-resistance to several other topoisomerase II (topo II) inhibitors, including mitoxantrone, daunomycin and etoposide. CHO-Adrr cells showed a lower (4-fold) level of cross-resistance to vincristine and colchicine, drugs associated with the multidrug-resistant phenotype. While CHO-Adrr cells showed no enhanced resistance to several mono- and bi-functional alkylating agents or to UV and ionizing radiation, they were greater than 80-fold resistant to mitomycin C (MMC). There was a 5-fold decreased level of daunomycin accumulation in CHO-Adrr cells compared to CHO-K1 cells and this was associated with increased drug efflux. The resistant cells had amplified multidrug resistance gene (mdr) sequences and overexpressed (mdr) mRNA. Verapamil was able to completely reverse Adriamycin resistance but reversal of MMC resistance was only partial, with residual 23-fold resistance. CHO-Adrr cells expressed a 4-fold reduced level of topo II protein but overexpressed an alpha class (basic) glutathione S-transferase (GST). Analysis of cell hybrids showed that while the level of resistance to Adriamycin dropped by a factor of 3 in CHO-K1/CHO-Adrr hybrids compared to CHO-Adrr/CHO-Adrr hybrids, resistance to MMC dropped 10-fold. Thus, CHO-Adrr cells appear to exhibit simultaneously several different drug resistance mechanisms including MDR and GST overexpression, and topo II reduction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311588     DOI: 10.1016/0006-2952(92)90231-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

Review 2.  Pharmacogenomics of cisplatin-induced ototoxicity.

Authors:  Debashree Mukherjea; Leonard P Rybak
Journal:  Pharmacogenomics       Date:  2011-07       Impact factor: 2.533

Review 3.  Glutathione-related enzymes, glutathione and multidrug resistance.

Authors:  J A Moscow; K H Dixon
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 4.  Cellular approaches to bioreductive drug mechanisms.

Authors:  A M Rauth; R S Marshall; B L Kuehl
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

5.  GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation.

Authors:  Simona Jurkovic Mlakar; Satyanarayana Chakradhara Rao Uppugunduri; Tiago Nava; Vid Mlakar; Hadrien Golay; Shannon Robin; Nicolas Waespe; Mohamed Aziz Rezgui; Yves Chalandon; Jaap Jan Boelens; Robert G M Bredius; Jean-Hugues Dalle; Christina Peters; Selim Corbacioglu; Henrique Bittencourt; Maja Krajinovic; Marc Ansari
Journal:  J Cancer Res Clin Oncol       Date:  2021-09-09       Impact factor: 4.553

6.  Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cells.

Authors:  R N Turner; N J Curtin
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.